Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • New Players Take the Field: How Private Employer Healthcare Could Mean More Focus on People

    Feb 25, 2020, 12:05 PM by Michael Croft

    Bio-IT World Contributed Commentary | Depending on which side of the gurney you find yourself, the U.S. healthcare system can be simultaneously viewed as either a modern-day gold rush or an impossible financial burden. In large part, this is because humans have been displaced by business objectives as the focal point of healthcare. If you’re seeking some sign of restored equilibrium between massive healthcare corporations (59 of the S&P 500 companies are healthcare-related) and the individuals they are meant to serve, there’s an inkling of real change, growing out of an unlikely corner… other massive corporations. 

    Full story
  • Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

    Feb 25, 2020, 10:09 AM by Michael Croft
    HOPKINTON, MA, UNITED STATES - Feb 25, 2020 - Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors
    Full story
  • The Pistoia Alliance’s UDM Project Reaches Major Milestone

    Feb 25, 2020, 09:15 AM by Michael Croft
    BOSTON, MA, UNITED STATES - Feb 25, 2020 - The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D, today released the latest Unified Data Model (UDM) file format, Version 6, supported by funding from Biovia, Elsevier, GSK, Novartis, and Roche (recently joined by BMS)
    Full story
  • Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc.

    Feb 25, 2020, 08:36 AM by Michael Croft
    PRINCETON, NJ - Feb 25, 2020 - Certara®, the global model-informed drug development and decision support leader, today reported that it has acquired a range of modeling and simulation technology assets from In Silico Biosciences, Inc
    Full story
  • LUNAC Therapeutics selects Domainex as its strategic drug discovery partner

    Feb 25, 2020, 04:50 AM by Michael Croft
    CAMBRIDGE AND LEEDS, UNITED KINGDOM - Feb 25, 2020 - Domainex Ltd., a fully integrated provider of drug discovery services from its Medicines Research Centre near Cambridge, UK, has entered into a research partnership with LUNAC Therapeutics Limited to discover novel anticoagulant therapies  that have a reduced risk of bleeding compared to current therapies
    Full story
  • Streck to present new tube at TRI-CON

    Feb 24, 2020, 10:20 AM by Michael Croft
    LA VISTA, NE - Feb 24, 2020 - Streck R&D Scientific Manager Dr. Nicholas George will give a presentation on our newest blood collection tube, RNA Complete BCT, at the 27th International Molecular Medicine Tri-Conference in San Francisco
    Full story
  • Rare Disease Patient Platform Raremark Partners With TriNetX

    Feb 24, 2020, 09:32 AM by Michael Croft
    CAMBRIDGE, MA - Feb 24, 2020 - TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced that Raremark, a patient-data platform focused on rare disease, has partnered with the TriNetX network to bring more clinical trials to its community
    Full story
  • Altair Medical awarded FDA Breakthrough Device designation to address the global opioid crisis

    Feb 24, 2020, 05:19 AM by Michael Croft
    GLASGOW, SCOTLAND - Feb 24, 2020 - Altair Medical, a medical technology company developing a groundbreaking solution to the global opioid crisis, today announce that the US Food and Drug Administration (FDA) has awarded the Company Breakthrough Device designation for its RESPMETER(TM) wearable biosensor device
    Full story
  • Aalto Bio Reagents Launches First Recombinant SARS-CoV-2 (COVID-19) Nucleocapsid Protein

    Feb 24, 2020, 05:13 AM by Michael Croft
    DUBLIN, IRELAND - Feb 24, 2020 - Aalto Bio Reagents today announced the availability of its new recombinant SARS-CoV-2 nucleocapsid protein (code CK 6404) for diagnostic test manufacturers, vaccine developers and researchers globally
    Full story
  • Creative Diagnostics Introduces Innovative Zebrafish Antibodies

    Feb 24, 2020, 03:31 AM by Michael Croft
    SHIRLEY, NY - Feb 25, 2020 - As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics now launches a large range of antibodies against key immune molecules in zebrafish to enhance the research within the fish scientific community as well as mammalian immune disorders researches
    Full story
  • MGI Announces April Availability Of Sequencers, Reagents In US

    Feb 21, 2020, 18:05 PM by Michael Croft
    Bio-IT World MGI, part of global genomics leader BGI Group, announced the commercial availability of its sequencing instruments and reagent kits in the United States based on MGI’s own innovative CoolMPS sequencing chemistry, starting in April of this year.
    Full story
  • Creative Proteomics Released BrdU Cell Proliferation Assay to Be Behind Researchers

    Feb 20, 2020, 21:48 PM by Michael Croft
    SHIRLEY, NY - Feb 21, 2020 - February 21, 2020, since its establishment in 2004, Creative Proteomics has served nearly 2 million researchers from different areas, including clinical, academia and industry
    Full story
  • The Value Of Imaging Data As The Missing Essential Component Of Real World Data

    Feb 20, 2020, 10:30 AM by Michael Croft
    Bio-IT World Contributed Commentary | Radiology is increasingly the key to synthesizing real world evidence with sufficient quality to shape drug performance. As a diagnostic toolset, imaging is one of the oldest and most widely used and clearly interpreted methods for measurement of outcomes. It is regularly used to measure disease progression and to determine the effectiveness of medical interventions. Imaging is also a common mechanism for early identification of disease that can be automated or extended through artificial intelligence (AI).
    Full story
  • Absolute Antibody Partners with the Technical University of Denmark to Offer Antibodies against Animal Venom Toxins

    Feb 20, 2020, 09:40 AM by Michael Croft
    REDCAR, UK - Feb 20, 2020 - Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with the Technical University of Denmark to develop engineered recombinant antibodies specific for animal toxins, such as toxins from snake venoms
    Full story
  • Follow the Money: Big Investments In CRISPR, Cell Therapies, Health Data Management

    Feb 19, 2020, 15:20 PM by Michael Croft
    Bio-IT World | Some big investments are driving CRISPR-based therapeutics, cell therapies, sepsis diagnostics and more this year. Unspecified investments by pharma are further propelling Seqster’s health data management platform.
    Full story
  • From Ending Addiction to Preventive Genomics, Bio-IT World 2020 Keynoters Share Data-Driven Approaches

    Feb 19, 2020, 13:30 PM by Michael Croft
    NEEDHAM, MA, UNITED STATES - Feb 19, 2020 - Bio-IT World 2020, the premier conference and expo uniting life science, data science, informatics and IT leaders, today announced its Plenary Keynote sessions
    Full story
  • Creative Biolabs Provides Anti-EGFR Therapeutic Antibody---Nimotuzumab for Research Use

    Feb 18, 2020, 23:09 PM by Michael Croft
    SHIRLEY, NY, USE - Feb 19, 2020 - February 19, 2020, Creative Biolabs, as a leading supplier in the recombinant antibody field, announced that the nimotuzumab, a kind of anti-EGFR therapeutic antibody, is now available for research and clinical use
    Full story
  • Greenphire and Roche Team to Address Critical Clinical Trial Patient Convenience Issues at 11th Annual SCOPE Summit

    Feb 18, 2020, 09:03 AM by Michael Croft
    ORLANDO, FL, UNITED STATES - Feb 18, 2020 - Greenphire, the global leader in financial software for clinical trials, today announced that it has teamed with top industry sponsor, Roche (SIX: RO, ROG;OTCQX: RHHBY), to address the top hurdles patients face when participating in clinical trials
    Full story
  • Signant Health invests for growth with the opening of its new Philadelphia-area office

    Feb 18, 2020, 08:57 AM by Michael Croft
    PHILADELPHIA - Feb 18, 2020 - Signant Health, an industry-leading clinical research technology and solutions company, is proud to announce that it has officially opened a new, leading edge office facility in Blue Bell, Pennsylvania
    Full story
  • Optibrium appoints Dr Tim Hohm as Director of Commercial Strategy and Business Development

    Feb 18, 2020, 08:50 AM by Michael Croft
    CAMBRIDGE, UNITED KINGDOM - Feb 18, 2020 - Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Tim Hohm as Director of Commercial Strategy and Business Development
    Full story
  • «
  • 211
  • 212
  • 213
  • 214 (current)
  • 215
  • 216
  • 217
  • 218
  • 219
  • 220
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy